We are live on !
Find out more
CS McKee Portfolio holdings
AUM
$1.09B
Turnover
3.92%
1-Year Est. Return
31.33%
This Fund
S&P 500
This Quarter Est. Return
+10.46%
1 Year Est. Return
+31.33%
3 Year Est. Return
+47.55%
5 Year Est. Return
+66.61%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
-$12.3M
(-1.1%)
Cap. Flow
-$107M
Cap. Flow % of AUM
Cap. Flow %
-9.83%
Top 10 Holdings %
Top 10 Hldgs %
32.88%
Holding
102
New
2
Increased
26
Reduced
65
Closed
2
Avg Time Held
4.9
years
Top 10 Avg Time Held
3.1
years
Top 20 Avg Time Held
2.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$9.5M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$8.6M |
| 3 |
Occidental Petroleum
OXY
|
+$2.05M |
| 4 |
Gilead Sciences
GILD
|
+$1.39M |
| 5 |
Freeport-McMoran
FCX
|
+$1.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$16M |
| 2 |
Kennametal
KMT
|
+$8.75M |
| 3 |
Apple
AAPL
|
+$7.48M |
| 4 |
Microsoft
MSFT
|
+$5.74M |
| 5 |
JPMorgan Chase
JPM
|
+$5.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.94% |
| 2 | Financials | 16.44% |
| 3 | Industrials | 13.05% |
| 4 | Healthcare | 12.6% |
| 5 | Communication Services | 12.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Matador Resources
MTDR
$7.1B
| $1.33M | 0.12% |
74,100
-1,150
| -2% | -$17.2K |
2017 Q3
9 quarters
|
|
77
Prestige Consumer Healthcare
PBH
$2.35B
| $1.31M | 0.12% |
32,440
+2,390
| +8% | +$89.2K |
2013 Q2
26 quarters
|
|
78
BancFirst
BANF
$3.63B
| $1.24M | 0.11% |
19,800
+450
| +2% | +$26.5K |
2017 Q2
10 quarters
|
|
79
Hancock Whitney
HWC
$5.82B
| $1.2M | 0.11% |
27,335
+247
| +0.9% | +$10K |
2013 Q2
26 quarters
|
|
80
First Interstate BancSystem
FIBK
$3.31B
| $1.19M | 0.11% |
28,370
+320
| +1% | +$13.4K |
2017 Q2
10 quarters
|
|
81
Benchmark Electronics
BHE
$2.55B
| $1.15M | 0.11% |
33,400
+1,300
| +4% | +$42.9K |
2013 Q2
26 quarters
|
|
82
Helios Technologies
HLIO
$2.23B
| $1.11M | 0.1% |
23,930
+1,130
| +5% | +$48.5K |
2013 Q2
26 quarters
|
|
83
TTM Technologies
TTMI
$10.4B
| $980K | 0.09% |
65,100
+2,850
| +5% | +$37.5K |
2013 Q2
26 quarters
|
|
84
PRA Group
PRAA
$739M
| $978K | 0.09% |
26,940
+1,740
| +7% | +$61.6K |
2013 Q2
26 quarters
|
|
85
Anika Therapeutics
ANIK
$271M
| $975K | 0.09% |
18,810
+1,860
| +11% | +$108K |
2016 Q1
15 quarters
|
|
86
Myriad Genetics
MYGN
$403M
| $926K | 0.08% |
34,000
-550
| -2% | -$15.1K |
2013 Q2
26 quarters
|
|
87
Cheesecake Factory
CAKE
$5.78B
| $842K | 0.08% |
21,670
+70
| +0.3% | +$2.89K |
2013 Q3
25 quarters
|
|
|
CISN
88
DELISTED
Cision Ltd. Ordinary Share
CISN
| $815K | 0.07% |
81,700
-1,300
| -2% | -$12.4K |
2018 Q3
5 quarters
|
|
89
Supernus Pharmaceuticals
SUPN
$2.32B
| $798K | 0.07% |
33,650
-500
| -1% | -$12.1K |
2016 Q2
14 quarters
|
|
90
DELISTED
Neenah, Inc. Common Stock
NP
| $789K | 0.07% |
11,200
-200
| -2% | -$13.6K |
2014 Q4
20 quarters
|
|
|
FOE
91
DELISTED
Ferro Corporation
FOE
| $648K | 0.06% |
43,690
+6,790
| +18% | +$87.6K |
2018 Q2
6 quarters
|
|
92
Allstate Corp 5.100% Fixed-To-Floating Rate Subordinated Debentures due 2053
ALL.PRB
$506M
| $586K | 0.05% |
22,000
+12,000
| +120% | +$319K |
2019 Q1
3 quarters
|
|
93
State Street Corp Series G Preferred Stock
STT.PRG
$396M
| $560K | 0.05% |
20,100
+10,000
| +99% | +$277K |
2018 Q1
7 quarters
|
|
94
NETSCOUT
NTCT
$2.81B
| $522K | 0.05% |
21,700
+200
| +0.9% | +$4.73K |
2014 Q1
23 quarters
|
|
95
Cooper-Standard Automotive
CPS
$362M
| $469K | 0.04% |
14,130
+2,980
| +27% | +$96.5K |
2015 Q2
18 quarters
|
|
|
96
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $452K | 0.04% |
+150,100
| New | +$390K |
2019 Q4
0 quarters
|
|
97
United Natural Foods
UNFI
$2.79B
| $449K | 0.04% |
51,250
-800
| -2% | -$6.45K |
2013 Q2
26 quarters
|
|
98
DELISTED
Bank of America Corporation Depositary Shares, each representing a 1/1,000th interest in a share of
BAC.PRC
| $288K | 0.03% |
11,000
| – | – |
2016 Q2
14 quarters
|
|
99
DELISTED
THE PNC FINANCIAL SERVICES GROUP, INC.
PNC.PRP
| $274K | 0.03% |
10,000
| – | – |
2019 Q1
3 quarters
|
|
|
MVC
100
DELISTED
MVC Capital, Inc.
MVC
| $242K | 0.02% |
26,400
-650
| -2% | -$5.86K |
2013 Q2
26 quarters
|
|
Similar funds
TRAM
SC
KGACF
BPWA
CS McKee's Q4 2019 Portfolio in Review
As of Q4 2019, CS McKee held 102 positions worth $1.09B, down 1.1% from $1.11B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
CS McKee withdrew a net $107M in Q4 2019, closing 2 positions and reducing 65 holdings. Its most notable exit was Celgene Corp, an estimated $16M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Industrials.
Against the trend, CS McKee opened a new position in Bristol-Myers Squibb worth $9.6M.
- CS McKee's largest Q4 2019 buy was Bristol-Myers Squibb: 150,100 shares worth $9.6M.
- CS McKee added most to RTX Corp in Q4 2019, an estimated $9.5M increase.
- CS McKee's biggest Q4 2019 reduction was Apple, cutting an estimated $7.48M.
- CS McKee fully exited Celgene Corp in Q4 2019, selling an estimated $16M.
- CS McKee's ten largest holdings make up 33% of its $1.09B portfolio in Q4 2019.
- CS McKee opened 2 new positions and closed 2 in Q4 2019.
- CS McKee's portfolio value fell 1.1% quarter-over-quarter to $1.09B.
Based on CS McKee's 13F filing for Q4 2019, filed 14 Feb 2020.